These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 2940946)

  • 1. Intra arterial ketanserin in peripheral vascular disease.
    Boas RA
    Angiology; 1986 Apr; 37(4):267-71. PubMed ID: 2940946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Ketanserin in the treatment of ischemic disease of the lower extremities].
    Gerová Z; Brimichová E; Dzúrik R
    Cas Lek Cesk; 1985 Jul; 124(30):938-41. PubMed ID: 3161617
    [No Abstract]   [Full Text] [Related]  

  • 3. Placebo-controlled double-blind trial of ketanserin in treatment of intermittent claudication.
    De Cree J; Leempoels J; Geukens H; Verhaegen H
    Lancet; 1984 Oct; 2(8406):775-9. PubMed ID: 6148522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is prevention of hypertension after open heart surgery possible by blocking 5HT2-receptors with ketanserin?
    van den Broeke JJ; Karliczek GF; Brenken U; Schokkenbroek R; Homan van der Heide JN
    Acta Anaesthesiol Belg; 1982; 33(2):115-20. PubMed ID: 6981913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study with the competitive 5-HT2-serotonergic antagonist ketanserin.
    Ferrara LA; Fasano ML; Rubba P; Soro S; Marotta G; Mancini M
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S159-60. PubMed ID: 2412041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous imaging of regional blood flow in peripheral vascular disease using Krypton-81m: effect of Ketanserin, a new selective serotonin antagonist.
    Gerritsen HA; Perquin JW; de Smet HL; Troost FA; Kotora OV
    Diagn Imaging; 1983; 52(2-3):85-92. PubMed ID: 6851822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Control of preeclamptic hypertension by ketanserin, a new serotonin receptor antagonist.
    Weiner CP; Socol ML; Vaisrub N
    Am J Obstet Gynecol; 1984 Jul; 149(5):496-500. PubMed ID: 6377898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ketanserin: a possible tool for studying the role of serotonin in hypertension.
    Woittiez AJ; Wenting GJ; Man in't Veld AJ; Boomsma F; Schalekamp MA
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S130-6. PubMed ID: 2412035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ketanserin in hypertension. Early clinical evaluation and dose finding study of a new 5-HT2 receptor antagonist.
    Andrén L; Svensson A; Dahlöf B; Eggertsen R; Hansson L
    Acta Med Scand; 1983; 214(2):125-30. PubMed ID: 6353879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experience with ketanserin, a serotonin (S2) antagonist, in longterm treatment of essential hypertension.
    Hedner T; Persson B; Berglund G
    Clin Exp Hypertens A; 1984; 6(3):743-51. PubMed ID: 6373066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Failure of ketanserin, a serotonin inhibitor, to prevent spontaneous or ergonovine-induced attacks of variant angina.
    Mata-Bourcart LA; Waters DD; Bouchard A; Miller DD; Théroux P
    Can J Cardiol; 1985; 1(3):168-71. PubMed ID: 2932205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ketanserin (5 HT2-antagonist) in secondary Raynaud's phenomenon.
    Bounameaux HM; Hellemans H; Verhaeghe R; Dequeker J
    J Cardiovasc Pharmacol; 1984; 6(5):975-6. PubMed ID: 6209510
    [No Abstract]   [Full Text] [Related]  

  • 13. Moderate essential hypertension control: a double-blind crossover study between a serotonin antagonist and a post-synaptic alpha-blocker.
    Rosenthal J; Koehle W; Gruebel B; Fisher R
    J Hypertens Suppl; 1986 Apr; 4(1):S85-7. PubMed ID: 2871145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ketanserin in acute superficial thrombophlebitis.
    de Roose J; Symoens J
    Lancet; 1982 Aug; 2(8295):440-1. PubMed ID: 6124830
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of ketanserin, a 5-HT2-receptor antagonist, on the blood flow response to temperature changes in the diabetic foot.
    Schneider SH; Tendler M; Apelian A; Jageneau AH; Khachadurian AK
    J Clin Pharmacol; 1985 Sep; 25(6):413-7. PubMed ID: 2932476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute effects of antagonist of S2-receptors.
    Petkovská N; Brimichová G; Tison P; Dzúrik R
    Czech Med; 1984; 7(4):210-4. PubMed ID: 6084584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atherosclerosis, peripheral arterial disease and the vascular response to ketanserin.
    Janicek M; Grassi CJ; Meyerovitz M; Callahan MB; Sandor T; Whittemore A; Mannick J; Harrington DP; Hollenberg NK
    Invest Radiol; 1990 May; 25(5):495-503. PubMed ID: 2345079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ketanserin in chronic sympathetic dystrophy. An acute controlled trial.
    Bounameaux HM; Hellemans H; Verhaeghe R
    Clin Rheumatol; 1984 Dec; 3(4):556-7. PubMed ID: 6084577
    [No Abstract]   [Full Text] [Related]  

  • 19. Role of ketanserin in the treatment of the essential arterial hypertension associated with ischemic heart disease.
    Podoleanu D; Cotoi S
    Rom J Intern Med; 1996; 34(1-2):49-54. PubMed ID: 8908630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of ketanserin, a 5-hydroxytryptamine receptor antagonist, for treatment of postoperative hypertension following coronary artery bypass surgery.
    van der Starre PJ; Scheijgrond HW; Reneman RS; Kolling JB
    Anesth Analg; 1983 Jan; 62(1):63-9. PubMed ID: 6600382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.